- Home
- VTLE vs TECX Comparison
VTLE vs TECX Comparison
Compare VTLE & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- TECX
- Stock Information
- Founded
- VTLE 2006
- TECX 2019
- Country
- VTLE United States
- TECX United States
- Employees
- VTLE N/A
- TECX N/A
- Industry
- VTLE
- TECX
- Sector
- VTLE
- TECX
- Exchange
- VTLE Nasdaq
- TECX Nasdaq
- Market Cap
- VTLE 591.0M
- TECX 334.4M
- IPO Year
- VTLE 2011
- TECX 2018
- Fundamental
- Price
- VTLE $15.61
- TECX $21.02
- Analyst Decision
- VTLE Hold
- TECX Buy
- Analyst Count
- VTLE 10
- TECX 6
- Target Price
- VTLE $28.63
- TECX $72.40
- AVG Volume (30 Days)
- VTLE 1.2M
- TECX 213.4K
- Earning Date
- VTLE 05-12-2025
- TECX 05-08-2025
- Dividend Yield
- VTLE N/A
- TECX N/A
- EPS Growth
- VTLE N/A
- TECX N/A
- EPS
- VTLE N/A
- TECX N/A
- Revenue
- VTLE $1,952,314,000.00
- TECX N/A
- Revenue This Year
- VTLE $9.36
- TECX N/A
- Revenue Next Year
- VTLE N/A
- TECX N/A
- P/E Ratio
- VTLE N/A
- TECX N/A
- Revenue Growth
- VTLE 26.15
- TECX N/A
- 52 Week Low
- VTLE $12.30
- TECX $1.40
- 52 Week High
- VTLE $53.88
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- VTLE 47.90
- TECX 53.43
- Support Level
- VTLE $13.46
- TECX $19.55
- Resistance Level
- VTLE $16.34
- TECX $21.99
- Average True Range (ATR)
- VTLE 0.87
- TECX 1.90
- MACD
- VTLE 0.32
- TECX 0.28
- Stochastic Oscillator
- VTLE 74.65
- TECX 74.82
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.